Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy
Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London
Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025
Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results
Helix BioPharma Responds to Market Activity
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM
Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting
Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025
Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group
Helix BioPharma Corp. (HBP.TO) Signs Capital Raising Agreement with Kerentech Consulting Ltd.
Helix BioPharma Corp. Appoints New COO and Communications Director to Accelerate Growth and Deliver on its Mission Against Hard-to-Treat Cancers
Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan
Helix BioPharma Corp. Announces Engagement of Independent Trading Group to Provide Market-Making Services
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025
Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain
Helix Biopharma Corp. Expands Leadership Team with World-Class Oncology and Scientific Experts
Helix BioPharma Corp. receives approval for the Extension of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing
Helix BioPharma Corp. Extends Date of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing
Helix BioPharma releases 1Q results as it works on developing roadmap for lung cancer drug by 2Q 2023
Helix BioPharma appoints Jacek Antas as CEO to replace Artur Gabor with immediate effect
Helix BioPharma closes private placement financing for net proceeds of C$4,629,019.86
Helix BioPharma advances clinical development of lead candidate L-DOS47, but manages to decrease R&D expenses in 2022 fiscal year
Helix BioPharma appoints Dr. Frank Gary Renshaw as Chief Medical Officer
Helix BioPharma Corp names Dr Gabrielle Siegers as its head of research and development
Helix BioPharma announces scientific collaboration with University Hospital Tuebingen in Germany
Helix BioPharma closes private placement financing for net proceeds of $2,002,000 with shareholder Jerzy Wilczewski
Helix BioPharma appoints Artur Gabor as its new CEO; adds three new board members
Helix BioPharma announces sudden passing of interim CEO Slawomir Majewski
Helix BioPharma closes a private placement financing for gross proceeds of $1,001,000 from the issuance of 3,850,000 common shares
Helix BioPharma says 2021 "a productive year" as it anticipates results of its Phase I and II studies in lung cancer in 2022
Helix BioPharma spends C$1.24M on R&D in its fiscal first quarter
Helix BioPharma increased crucial spending on research and development for the 2021 fiscal year
Helix BioPharma appoints paediatric surgeon Dr. Krzysztof Saczek to its board of directors
Helix BioPharma plans management shakeup in September
Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants
Wall Street takes a turn for the worse as investors eye Fed
Helix BioPharma advancing efforts to combat killer cancers with unique immuno-oncology therapies
Helix BioPharma spends C$1.9M on R&D in its fiscal third quarter